Dexmedetomidine Combined With Lidocaine Infusion Affect Inflammation Cytokines
- Conditions
- Anesthesia; Reaction
- Interventions
- Registration Number
- NCT03276533
- Lead Sponsor
- Anqing Municipal Hospital
- Brief Summary
Objective: The present study was to evaluate the effects of dexmedetomidine alone, lidocaine alone and their combined infusion on postoperative inflammation cytokines after Laparoscopic hysterectomy.
Methods: Investigators enrolled 160 women with American Society of Anesthesiologists (ASA) physical status I and II, aged 40-65 years, and scheduled for elective laparoscopic hysterectomy with general anesthesia from October 2017 to August 2018. The participants were randomly assigned into four groups(n=40 each group): group CON received normal saline infusion, group LIDO received lidocaine infusion (1.5 mg/kg loading, 1.5 mg/kg/h infusion), group DEX received dexmedetomidine infusion (0.5 µg/kg loading, 0.4 µg/kg/h infusion) and group LIDO+DEX received lidocaine (1.5 mg/kg loading, 1.5 mg/kg/h infusion) and dexmedetomidine infusions (0.5 µg/kg loading, 0.4 µg/kg/h infusion). The four groups received an IV bolus infusion of normal saline, lidocaine, dexmedetomidine and lidocaine combined with dexmedetomidine respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion of normal saline, lidocaine, dexmedetomidine and lidocaine combined with dexmedetomidine until abdominal wound closure, respectively. Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), the end of surgery (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 160
- American Society of Anesthesiologists (ASA) physical status I and II
- weighted 50 kg-65 kg
- aged 40-65 yr
- elective laparoscopic hysterectomy with general anesthesia
- a history of allergy to local anesthetics
- severe respiratory, renal or hepatic disease
- preoperative opioids medication
- psychiatric medical history
- Patients with severe hypotension [mean arterial pressure (MAP<60 mmHg)] or bradycardia [heart rate (HR) <40 beats per minute (bpm)], arrhythmia, or urticaria due to lidocaine and dexmedetomidine infusion during the surgery
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Intravenous saline, dexmedetomidine and lidocaine Saline - Intravenous saline, dexmedetomidine and lidocaine Lidocaine - Intravenous saline, dexmedetomidine and lidocaine Lidocaine plus Dexmedetomidine - Intravenous saline, dexmedetomidine, lidocaine and combination Saline - Intravenous saline, dexmedetomidine, lidocaine and combination Lidocaine plus Dexmedetomidine - Intravenous saline,dexmedetomidine plus lidocaine Saline - Intravenous saline,dexmedetomidine plus lidocaine Lidocaine plus Dexmedetomidine - Intravenous saline, dexmedetomidine combined with lidocaine Saline - Intravenous saline, dexmedetomidine combined with lidocaine Lidocaine plus Dexmedetomidine - Intravenous saline, dexmedetomidine and lidocaine Dexmedetomidine - Intravenous saline, dexmedetomidine, lidocaine and combination Lidocaine - Intravenous saline, dexmedetomidine, lidocaine and combination Dexmedetomidine - Intravenous saline,dexmedetomidine plus lidocaine Lidocaine - Intravenous saline,dexmedetomidine plus lidocaine Dexmedetomidine - Intravenous saline, dexmedetomidine combined with lidocaine Lidocaine - Intravenous saline, dexmedetomidine combined with lidocaine Dexmedetomidine -
- Primary Outcome Measures
Name Time Method Interleukin-6 postoperative 24 hours Interleukin-6 level in serum was measured at the before administration of drugs (T1), Interleukin-6 level in serum was measured at the end of the operation (T2); Interleukin-6 level in serum was measured at the postoperative 2 hour (T3); Interleukin-6 level in serum was measured at the postoperative 24 hour (T4)
Tumor necrosis factor-α postoperative 24 hours Tumor necrosis factor-α level in serum was measured at the before administration of drugs (T1); Tumor necrosis factor-α level in serum was measured at the end of the operation (T2); Tumor necrosis factor-α level in serum was measured at the postoperative 2 hour (T3); Tumor necrosis factor-α level in serum was measured at the postoperative 24 hour (T4)
Interleukin-1 postoperative 24 hours Interleukin-1 level in serum was measured at the before administration of drugs (T1); Interleukin-1 level in serum was measured at the end of the operation (T2); Interleukin-1 level in serum was measured at the postoperative 2 hour (T3); Interleukin-1 level in serum was measured at the postoperative 24 hour (T4)
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Department of Anqing Hospital Anesthesiology
🇨🇳Anqing, Anhui, China